6 news items
CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine
ARCT
CSLLY
20 May 24
announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
Nature Communications has published results from an integrated phase 1/2/3a
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
(NASDAQ:ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
ARCT
11 Mar 24
attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
ARCT
7 Mar 24
a longer duration of immunity compared to conventional COVID-19 mRNA vaccine booster. Short communication follows previously published data
bi16g934i6ypf8upr3p4fq67bgo123o02eno9etqda43d
ABM
AEO
AFCG
7 Mar 24
(NYSE:WLYB) is expected to report earnings for its third quarter.
• Sequans Communications
- Prev
- 1
- Next